← Leaderboards
Victor John Thannickal
Southeast Louisiana Veterans Health Care
$20,353,946
Attributed
$25,736,306
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,558,855 · 17
VA$0 · 1
By mechanism
P01$22,068,330 · 5
R01$16,308,145 · 7
T32$2,755,619 · 1
P50$2,103,208 · 2
P42$210,099 · 1
K08$113,454 · 1
Top collaborators
- Yan Sanders6 shared
- Jaroslaw Waldemar Zmijewski6 shared
- Jarrod W. Barnes4 shared
- Subramaniam Pennathur4 shared
Others in their field
Top investigators on “Fibrosis”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Peter Scott Heeger · Case Western Reserve University$58,406,959
- John F Engelhardt · University Of Iowa$51,265,353
- David Albert Schwartz · Va Eastern Colorado Health Care System$41,842,857
- Richard C Boucher · University Of North Carolina Chapel Hill$33,165,173
- Bruce A. Stanton · Dartmouth College$32,494,343
Research focus
FibrosisMyofibroblastPulmonary FibrosisLung DiseasesLungFibroblastsLung InjuryPhenotypeApoptosisCellsSignal TransductionResponseMediatingTissuesPharmaceutical PreparationsEnzymesIn VivoResistanceResolutionTherapeutic TargetNadph OxidaseIdiopathic Pulmonary FibrosisPathogenesisMitochondria
Grant awards (91)
AMPK in the Development and resolution of Lung Fibrosis$749,246
R01 · FY2025 · HL
Metabolic Reprogramming of the Alveolar Stem Cell Niche in Pulmonary Fibrosis$603,881
R01 · FY2025 · HL · contact PI
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$438,138
R01 · FY2025 · HL
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2025 · VA · contact PI
AMPK in the Development and resolution of Lung Fibrosis$761,371
R01 · FY2024 · HL
Metabolic Reprogramming of the Alveolar Stem Cell Niche in Pulmonary Fibrosis$609,272
R01 · FY2024 · HL · contact PI
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$343,311
R01 · FY2024 · HL
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$95,543
R01 · FY2024 · HL
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2024 · VA · contact PI
Metabolic Landscape of the Aging Lung$785,329
R01 · FY2023 · HL
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$512,796
R01 · FY2023 · HL
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2023 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,194,222
P01 · FY2022 · HL · contact PI
Metabolic Landscape of the Aging Lung$785,329
R01 · FY2022 · HL
AMPK in the Development and Resolution of Lung Fibrosis$528,465
R01 · FY2022 · HL
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$526,161
R01 · FY2022 · HL
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2022 · VA · contact PI
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2022 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,499,930
P01 · FY2021 · HL · contact PI
Metabolic Landscape of the Aging Lung$785,329
R01 · FY2021 · HL
Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis$529,716
R01 · FY2021 · HL
AMPK in the Development and Resolution of Lung Fibrosis$528,465
R01 · FY2021 · HL
Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts$390,755
P01 · FY2021 · HL · contact PI
Administrative and Biostatistical Core$104,799
P01 · FY2021 · HL · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,358,571
P01 · FY2020 · HL · contact PI
Metabolic Landscape of the Aging Lung$797,454
R01 · FY2020 · HL
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$532,334
P01 · FY2020 · HL · contact PI
AMPK in the Development and Resolution of Lung Fibrosis$528,465
R01 · FY2020 · HL
Project 2 Asthma in Children Exposed to Heavy Metals$210,099
P42 · FY2020 · ES · contact PI
Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts$116,132
P01 · FY2020 · HL · contact PI
Administrative and Biostatistical Core$29,803
P01 · FY2020 · HL · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,939,405
P01 · FY2019 · HL · contact PI
AMPK in the Development and Resolution of Lung Fibrosis$528,465
R01 · FY2019 · HL
Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts$408,371
P01 · FY2019 · HL · contact PI
Administrative and Biostatistical Core$104,799
P01 · FY2019 · HL · contact PI
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2019 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,671,476
P01 · FY2018 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$460,252
T32 · FY2018 · HL · contact PI
Redox Regulation of Metabolic Reprogramming in Activated Myofibroblasts$366,794
P01 · FY2018 · HL · contact PI
Myofibroblast Senescence in Pulmonary Fibrosis$330,750
R01 · FY2018 · AG · contact PI
Administrative and Biostatistical Core$104,799
P01 · FY2018 · HL · contact PI
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2018 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,956,371
P01 · FY2017 · HL · contact PI
N0X4 as a Therapeutic Target in IPF$380,561
P01 · FY2017 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$346,463
T32 · FY2017 · HL · contact PI
Myofibroblast Senescence in Pulmonary Fibrosis$330,750
R01 · FY2017 · AG · contact PI
Administrative and Biostatistics Core$140,119
P01 · FY2017 · HL · contact PI
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2017 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,956,371
P01 · FY2016 · HL · contact PI
N0X4 as a Therapeutic Target in IPF$380,561
P01 · FY2016 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$368,701
T32 · FY2016 · HL · contact PI
Myofibroblast Senescence in Pulmonary Fibrosis$330,750
R01 · FY2016 · AG · contact PI
Administrative and Biostatistics Core$140,119
P01 · FY2016 · HL · contact PI
Sirtuins in Lung Aging and Fibrosis$0
I01 · FY2016 · VA · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,927,027
P01 · FY2015 · HL · contact PI
N0X4 as a Therapeutic Target in IPF$389,536
P01 · FY2015 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$362,408
T32 · FY2015 · HL · contact PI
Myofibroblast Senescence in Pulmonary Fibrosis$320,827
R01 · FY2015 · AG · contact PI
Administrative and Biostatistics Core$143,424
P01 · FY2015 · HL · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,917,246
P01 · FY2014 · HL · contact PI
N0X4 as a Therapeutic Target in IPF$387,559
P01 · FY2014 · HL · contact PI
Myofibroblast Senescence in Pulmonary Fibrosis$330,750
R01 · FY2014 · AG · contact PI
Training Program in Lung Biology and Translational Medicine$211,659
T32 · FY2014 · HL · contact PI
Administrative and Biostatistics Core$142,695
P01 · FY2014 · HL · contact PI
Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease$1,869,596
P01 · FY2013 · HL · contact PI
N0X4 as a Therapeutic Target in IPF$376,376
P01 · FY2013 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$266,174
T32 · FY2013 · HL · contact PI
Administrative and Biostatistics Core$138,579
P01 · FY2013 · HL · contact PI
Rho-Kinase Pathway in Pulmonary Fibrosis$439,500
P50 · FY2012 · HL · contact PI
Mass Spectrometry-Based Biomarker Discovery$382,388
R01 · FY2012 · HL
Training Program in Lung Biology and Translational Medicine$338,532
T32 · FY2012 · HL · contact PI
Rho-Kinase Pathway in Pulmonary Fibrosis$439,500
P50 · FY2011 · HL · contact PI
Mass Spectrometry-Based Biomarker Discovery$386,250
R01 · FY2011 · HL
Oxidants and TGF-beta in Myofibroblast Differentiation/Survival$362,693
R01 · FY2011 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$269,143
T32 · FY2011 · HL · contact PI
Mass Spectrometry-Based Biomarker Discovery$386,250
R01 · FY2010 · HL
Oxidants and TGF-beta in Myofibroblast Differentiation/Survival$362,797
R01 · FY2010 · HL · contact PI
Training Program in Lung Biology and Translational Medicine$132,287
T32 · FY2010 · HL · contact PI
Mass Spectrometry-Based Biomarker Discovery$386,250
R01 · FY2009 · HL
Oxidants and TGF-beta in Myofibroblast Differentiation/Survival$362,594
R01 · FY2009 · HL · contact PI
Oxidants and TGF-beta in Myofibroblast Differentiation/Survival$376,360
R01 · FY2008 · HL · contact PI
Alveolar Mesenchymal Cells in Acute Lung Injury$397,750
P50 · FY2007 · HL · contact PI
Alveolar Mesenchymal Cells in Acute Lung Injury$239,746
P50 · FY2006 · HL · contact PI
Alveolar Mesenchymal Cells in Acute Lung Injury$235,386
P50 · FY2005 · HL
Oxidants and TGF-Beta in Myofibroblast Differentiation$302,000
R01 · FY2004 · HL
Alveolar Mesenchymal Cells in Acute Lung Injury$351,326
P50 · FY2003 · HL
Oxidants and TGF-Beta in Myofibroblast Differentiation$302,000
R01 · FY2003 · HL
Oxidants and TGF-Beta in Myofibroblast Differentiation$302,000
R01 · FY2002 · HL
Oxidants and TGF-Beta in Myofibroblast Differentiation$280,886
R01 · FY2001 · HL
Oxidants and TGF-Beta in Myofibroblast Differentiation$35,114
R01 · FY2001 · HL
REACTIVE OXYGEN SPECIES AS MEDIATORS OF TGF-B1 ACTIONS$113,454
K08 · FY2000 · HL